News | December 15, 2021
NATCO Pharma to acquire Dash Pharmaceuticals
The cash consideration for the acquisition is US$ 18 million.
The cash consideration for the acquisition is US$ 18 million.
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
The group now has 325 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
As part of the out-licensing deal with Tabuk, Biocon will develop and manufacture the products, and Tabuk will commercialise them
Collectively, these 10 laboratories are capable of processing about 10,000 samples in a day and deliver results within the given turnaround time
Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)
According to the Russian Direct Investment Fund (RDIF), the Russian Sputnik V and Sputnik Light vaccines have proven to be highly effective against all variants of SARC-Cov-2
Rad-G is a rugged, portable, handheld Masimo SET Measure-through Motion and Low Perfusion pulse oximeter and noninvasive respiration rate monitor
Merck has shared these additional analyses with the FDA and they will be presented to the FDA’s Antimicrobial Drugs Advisory Committee on Nov. 30th
Subscribe To Our Newsletter & Stay Updated
